DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. is a phase 2/3, interventional study registered as NCT05768178 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2023-03-01 and due to reach its primary completion in 2029-10. Interventions recorded: Vemurafenib; Cobimetinib. Conditions listed: Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic; Solid Tumour. Primary outcome: Objective Response (OR); Durable Clinical Benefit (DCB). Colorectal eligibility wording from the registry: "Patients with QTcF (Corrected QT interval by Fridericia) at screening of \>450 ms for males and \>470 ms for females measured on triplicate ECG (if 1/3 readings show \>450/470 ms then patient is ineligible)". Sites: United Kingdom. United Kingdom sites listed: 16. No results are recorded here; the registry entry is the source.